The Experts below are selected from a list of 10029 Experts worldwide ranked by ideXlab platform
Gyong Moon Kim - One of the best experts on this subject based on the ideXlab platform.
-
the efficacy of 308 nm excimer laser light el and Topical Agent combination therapy versus el monotherapy for vitiligo a systematic review and meta analysis of randomized controlled trials rcts
Journal of The American Academy of Dermatology, 2016Co-Authors: Jung Min Bae, Bo Young Hong, Joo Hee Lee, Ji Hae Lee, Gyong Moon KimAbstract:Background Combination therapies of excimer laser/light (EL) and various Topical Agents are widely used in the treatment of vitiligo. Objective We sought to compare the efficacy of EL and Topical Agent combination therapy versus EL monotherapy for vitiligo. Methods Manual searches of reference lists and computerized searches of the MEDLINE, EMBASE, and Cochrane library (from inception through December 15, 2014) were conducted to identify randomized controlled trials that assessed the efficacy of EL alone or in combination with Topical Agents for vitiligo. The primary outcome was treatment success (≥75% repigmentation), and the secondary outcome was treatment failure ( Results We analyzed 8 randomized controlled trials comprising a total of 425 patches/patients. The combination of EL and Topical calcineurin inhibitors (4 studies: relative risk 1.93, 95% confidence interval 1.28-2.91; number needed to treat 4.5, 95% confidence interval 2.9-10) was superior to EL monotherapy for vitiligo. There was insufficient evidence to support beneficial effects of Topical vitamin-D3 analogs (3 studies) and corticosteroids (1 study). Limitations These findings are based on small numbers of randomized controlled trials and heterogeneities among included studies are another limitation. Conclusion Topical calcineurin inhibitors in conjunction with EL are more effective compared with EL monotherapy.
-
The efficacy of 308-nm excimer laser/light (EL) and Topical Agent combination therapy versus EL monotherapy for vitiligo: A systematic review and meta-analysis of randomized controlled trials (RCTs).
Journal of the American Academy of Dermatology, 2016Co-Authors: Jung Min Bae, Bo Young Hong, Joo Hee Lee, Ji Hae Lee, Gyong Moon KimAbstract:Combination therapies of excimer laser/light (EL) and various Topical Agents are widely used in the treatment of vitiligo. We sought to compare the efficacy of EL and Topical Agent combination therapy versus EL monotherapy for vitiligo. Manual searches of reference lists and computerized searches of the MEDLINE, EMBASE, and Cochrane library (from inception through December 15, 2014) were conducted to identify randomized controlled trials that assessed the efficacy of EL alone or in combination with Topical Agents for vitiligo. The primary outcome was treatment success (≥75% repigmentation), and the secondary outcome was treatment failure (<25% repigmentation); meta-analyses were performed when possible. We analyzed 8 randomized controlled trials comprising a total of 425 patches/patients. The combination of EL and Topical calcineurin inhibitors (4 studies: relative risk 1.93, 95% confidence interval 1.28-2.91; number needed to treat 4.5, 95% confidence interval 2.9-10) was superior to EL monotherapy for vitiligo. There was insufficient evidence to support beneficial effects of Topical vitamin-D3 analogs (3 studies) and corticosteroids (1 study). These findings are based on small numbers of randomized controlled trials and heterogeneities among included studies are another limitation. Topical calcineurin inhibitors in conjunction with EL are more effective compared with EL monotherapy. Copyright © 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
Jung Min Bae - One of the best experts on this subject based on the ideXlab platform.
-
the efficacy of 308 nm excimer laser light el and Topical Agent combination therapy versus el monotherapy for vitiligo a systematic review and meta analysis of randomized controlled trials rcts
Journal of The American Academy of Dermatology, 2016Co-Authors: Jung Min Bae, Bo Young Hong, Joo Hee Lee, Ji Hae Lee, Gyong Moon KimAbstract:Background Combination therapies of excimer laser/light (EL) and various Topical Agents are widely used in the treatment of vitiligo. Objective We sought to compare the efficacy of EL and Topical Agent combination therapy versus EL monotherapy for vitiligo. Methods Manual searches of reference lists and computerized searches of the MEDLINE, EMBASE, and Cochrane library (from inception through December 15, 2014) were conducted to identify randomized controlled trials that assessed the efficacy of EL alone or in combination with Topical Agents for vitiligo. The primary outcome was treatment success (≥75% repigmentation), and the secondary outcome was treatment failure ( Results We analyzed 8 randomized controlled trials comprising a total of 425 patches/patients. The combination of EL and Topical calcineurin inhibitors (4 studies: relative risk 1.93, 95% confidence interval 1.28-2.91; number needed to treat 4.5, 95% confidence interval 2.9-10) was superior to EL monotherapy for vitiligo. There was insufficient evidence to support beneficial effects of Topical vitamin-D3 analogs (3 studies) and corticosteroids (1 study). Limitations These findings are based on small numbers of randomized controlled trials and heterogeneities among included studies are another limitation. Conclusion Topical calcineurin inhibitors in conjunction with EL are more effective compared with EL monotherapy.
-
The efficacy of 308-nm excimer laser/light (EL) and Topical Agent combination therapy versus EL monotherapy for vitiligo: A systematic review and meta-analysis of randomized controlled trials (RCTs).
Journal of the American Academy of Dermatology, 2016Co-Authors: Jung Min Bae, Bo Young Hong, Joo Hee Lee, Ji Hae Lee, Gyong Moon KimAbstract:Combination therapies of excimer laser/light (EL) and various Topical Agents are widely used in the treatment of vitiligo. We sought to compare the efficacy of EL and Topical Agent combination therapy versus EL monotherapy for vitiligo. Manual searches of reference lists and computerized searches of the MEDLINE, EMBASE, and Cochrane library (from inception through December 15, 2014) were conducted to identify randomized controlled trials that assessed the efficacy of EL alone or in combination with Topical Agents for vitiligo. The primary outcome was treatment success (≥75% repigmentation), and the secondary outcome was treatment failure (<25% repigmentation); meta-analyses were performed when possible. We analyzed 8 randomized controlled trials comprising a total of 425 patches/patients. The combination of EL and Topical calcineurin inhibitors (4 studies: relative risk 1.93, 95% confidence interval 1.28-2.91; number needed to treat 4.5, 95% confidence interval 2.9-10) was superior to EL monotherapy for vitiligo. There was insufficient evidence to support beneficial effects of Topical vitamin-D3 analogs (3 studies) and corticosteroids (1 study). These findings are based on small numbers of randomized controlled trials and heterogeneities among included studies are another limitation. Topical calcineurin inhibitors in conjunction with EL are more effective compared with EL monotherapy. Copyright © 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
Ji Hae Lee - One of the best experts on this subject based on the ideXlab platform.
-
the efficacy of 308 nm excimer laser light el and Topical Agent combination therapy versus el monotherapy for vitiligo a systematic review and meta analysis of randomized controlled trials rcts
Journal of The American Academy of Dermatology, 2016Co-Authors: Jung Min Bae, Bo Young Hong, Joo Hee Lee, Ji Hae Lee, Gyong Moon KimAbstract:Background Combination therapies of excimer laser/light (EL) and various Topical Agents are widely used in the treatment of vitiligo. Objective We sought to compare the efficacy of EL and Topical Agent combination therapy versus EL monotherapy for vitiligo. Methods Manual searches of reference lists and computerized searches of the MEDLINE, EMBASE, and Cochrane library (from inception through December 15, 2014) were conducted to identify randomized controlled trials that assessed the efficacy of EL alone or in combination with Topical Agents for vitiligo. The primary outcome was treatment success (≥75% repigmentation), and the secondary outcome was treatment failure ( Results We analyzed 8 randomized controlled trials comprising a total of 425 patches/patients. The combination of EL and Topical calcineurin inhibitors (4 studies: relative risk 1.93, 95% confidence interval 1.28-2.91; number needed to treat 4.5, 95% confidence interval 2.9-10) was superior to EL monotherapy for vitiligo. There was insufficient evidence to support beneficial effects of Topical vitamin-D3 analogs (3 studies) and corticosteroids (1 study). Limitations These findings are based on small numbers of randomized controlled trials and heterogeneities among included studies are another limitation. Conclusion Topical calcineurin inhibitors in conjunction with EL are more effective compared with EL monotherapy.
-
The efficacy of 308-nm excimer laser/light (EL) and Topical Agent combination therapy versus EL monotherapy for vitiligo: A systematic review and meta-analysis of randomized controlled trials (RCTs).
Journal of the American Academy of Dermatology, 2016Co-Authors: Jung Min Bae, Bo Young Hong, Joo Hee Lee, Ji Hae Lee, Gyong Moon KimAbstract:Combination therapies of excimer laser/light (EL) and various Topical Agents are widely used in the treatment of vitiligo. We sought to compare the efficacy of EL and Topical Agent combination therapy versus EL monotherapy for vitiligo. Manual searches of reference lists and computerized searches of the MEDLINE, EMBASE, and Cochrane library (from inception through December 15, 2014) were conducted to identify randomized controlled trials that assessed the efficacy of EL alone or in combination with Topical Agents for vitiligo. The primary outcome was treatment success (≥75% repigmentation), and the secondary outcome was treatment failure (<25% repigmentation); meta-analyses were performed when possible. We analyzed 8 randomized controlled trials comprising a total of 425 patches/patients. The combination of EL and Topical calcineurin inhibitors (4 studies: relative risk 1.93, 95% confidence interval 1.28-2.91; number needed to treat 4.5, 95% confidence interval 2.9-10) was superior to EL monotherapy for vitiligo. There was insufficient evidence to support beneficial effects of Topical vitamin-D3 analogs (3 studies) and corticosteroids (1 study). These findings are based on small numbers of randomized controlled trials and heterogeneities among included studies are another limitation. Topical calcineurin inhibitors in conjunction with EL are more effective compared with EL monotherapy. Copyright © 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
Joo Hee Lee - One of the best experts on this subject based on the ideXlab platform.
-
the efficacy of 308 nm excimer laser light el and Topical Agent combination therapy versus el monotherapy for vitiligo a systematic review and meta analysis of randomized controlled trials rcts
Journal of The American Academy of Dermatology, 2016Co-Authors: Jung Min Bae, Bo Young Hong, Joo Hee Lee, Ji Hae Lee, Gyong Moon KimAbstract:Background Combination therapies of excimer laser/light (EL) and various Topical Agents are widely used in the treatment of vitiligo. Objective We sought to compare the efficacy of EL and Topical Agent combination therapy versus EL monotherapy for vitiligo. Methods Manual searches of reference lists and computerized searches of the MEDLINE, EMBASE, and Cochrane library (from inception through December 15, 2014) were conducted to identify randomized controlled trials that assessed the efficacy of EL alone or in combination with Topical Agents for vitiligo. The primary outcome was treatment success (≥75% repigmentation), and the secondary outcome was treatment failure ( Results We analyzed 8 randomized controlled trials comprising a total of 425 patches/patients. The combination of EL and Topical calcineurin inhibitors (4 studies: relative risk 1.93, 95% confidence interval 1.28-2.91; number needed to treat 4.5, 95% confidence interval 2.9-10) was superior to EL monotherapy for vitiligo. There was insufficient evidence to support beneficial effects of Topical vitamin-D3 analogs (3 studies) and corticosteroids (1 study). Limitations These findings are based on small numbers of randomized controlled trials and heterogeneities among included studies are another limitation. Conclusion Topical calcineurin inhibitors in conjunction with EL are more effective compared with EL monotherapy.
-
The efficacy of 308-nm excimer laser/light (EL) and Topical Agent combination therapy versus EL monotherapy for vitiligo: A systematic review and meta-analysis of randomized controlled trials (RCTs).
Journal of the American Academy of Dermatology, 2016Co-Authors: Jung Min Bae, Bo Young Hong, Joo Hee Lee, Ji Hae Lee, Gyong Moon KimAbstract:Combination therapies of excimer laser/light (EL) and various Topical Agents are widely used in the treatment of vitiligo. We sought to compare the efficacy of EL and Topical Agent combination therapy versus EL monotherapy for vitiligo. Manual searches of reference lists and computerized searches of the MEDLINE, EMBASE, and Cochrane library (from inception through December 15, 2014) were conducted to identify randomized controlled trials that assessed the efficacy of EL alone or in combination with Topical Agents for vitiligo. The primary outcome was treatment success (≥75% repigmentation), and the secondary outcome was treatment failure (<25% repigmentation); meta-analyses were performed when possible. We analyzed 8 randomized controlled trials comprising a total of 425 patches/patients. The combination of EL and Topical calcineurin inhibitors (4 studies: relative risk 1.93, 95% confidence interval 1.28-2.91; number needed to treat 4.5, 95% confidence interval 2.9-10) was superior to EL monotherapy for vitiligo. There was insufficient evidence to support beneficial effects of Topical vitamin-D3 analogs (3 studies) and corticosteroids (1 study). These findings are based on small numbers of randomized controlled trials and heterogeneities among included studies are another limitation. Topical calcineurin inhibitors in conjunction with EL are more effective compared with EL monotherapy. Copyright © 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
Bo Young Hong - One of the best experts on this subject based on the ideXlab platform.
-
the efficacy of 308 nm excimer laser light el and Topical Agent combination therapy versus el monotherapy for vitiligo a systematic review and meta analysis of randomized controlled trials rcts
Journal of The American Academy of Dermatology, 2016Co-Authors: Jung Min Bae, Bo Young Hong, Joo Hee Lee, Ji Hae Lee, Gyong Moon KimAbstract:Background Combination therapies of excimer laser/light (EL) and various Topical Agents are widely used in the treatment of vitiligo. Objective We sought to compare the efficacy of EL and Topical Agent combination therapy versus EL monotherapy for vitiligo. Methods Manual searches of reference lists and computerized searches of the MEDLINE, EMBASE, and Cochrane library (from inception through December 15, 2014) were conducted to identify randomized controlled trials that assessed the efficacy of EL alone or in combination with Topical Agents for vitiligo. The primary outcome was treatment success (≥75% repigmentation), and the secondary outcome was treatment failure ( Results We analyzed 8 randomized controlled trials comprising a total of 425 patches/patients. The combination of EL and Topical calcineurin inhibitors (4 studies: relative risk 1.93, 95% confidence interval 1.28-2.91; number needed to treat 4.5, 95% confidence interval 2.9-10) was superior to EL monotherapy for vitiligo. There was insufficient evidence to support beneficial effects of Topical vitamin-D3 analogs (3 studies) and corticosteroids (1 study). Limitations These findings are based on small numbers of randomized controlled trials and heterogeneities among included studies are another limitation. Conclusion Topical calcineurin inhibitors in conjunction with EL are more effective compared with EL monotherapy.
-
The efficacy of 308-nm excimer laser/light (EL) and Topical Agent combination therapy versus EL monotherapy for vitiligo: A systematic review and meta-analysis of randomized controlled trials (RCTs).
Journal of the American Academy of Dermatology, 2016Co-Authors: Jung Min Bae, Bo Young Hong, Joo Hee Lee, Ji Hae Lee, Gyong Moon KimAbstract:Combination therapies of excimer laser/light (EL) and various Topical Agents are widely used in the treatment of vitiligo. We sought to compare the efficacy of EL and Topical Agent combination therapy versus EL monotherapy for vitiligo. Manual searches of reference lists and computerized searches of the MEDLINE, EMBASE, and Cochrane library (from inception through December 15, 2014) were conducted to identify randomized controlled trials that assessed the efficacy of EL alone or in combination with Topical Agents for vitiligo. The primary outcome was treatment success (≥75% repigmentation), and the secondary outcome was treatment failure (<25% repigmentation); meta-analyses were performed when possible. We analyzed 8 randomized controlled trials comprising a total of 425 patches/patients. The combination of EL and Topical calcineurin inhibitors (4 studies: relative risk 1.93, 95% confidence interval 1.28-2.91; number needed to treat 4.5, 95% confidence interval 2.9-10) was superior to EL monotherapy for vitiligo. There was insufficient evidence to support beneficial effects of Topical vitamin-D3 analogs (3 studies) and corticosteroids (1 study). These findings are based on small numbers of randomized controlled trials and heterogeneities among included studies are another limitation. Topical calcineurin inhibitors in conjunction with EL are more effective compared with EL monotherapy. Copyright © 2015 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.
